Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 6/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | IL1B | P01584 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 2/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12126160 | 0.85 | KDM4E (0.42) | KMOMCL1KDM4EIL1BKDM5A | |
| SCHEMBL12126164 | 0.75 | KMO (0.45) | KMOMCL1KDM4EAKR1C2AKR1C1 | |
| SCHEMBL13117990 | 0.73 | KMO (0.55) | KMOKDM4EKDM5AKDM5BKDM4A | |
| SCHEMBL22245529 | 0.71 | KDM4E (0.47) | KMOKDM4EKDM5AKDM5BKDM4A | |
| SCHEMBL12126161 | 0.70 | KMO (0.45) | KMOMCL1KDM4EXDHSLC22A12 | |
| SCHEMBL13118031 | 0.70 | KDM4E (0.42) | MCL1KDM4EKDM5AKDM5BKDM4A | |
| SCHEMBL13108539 | 0.70 | ALDH1A1 (0.41) | KMOMCL1KDM4EKDM5AKDM5B | |
| SCHEMBL13108529 | 0.68 | CTRC (0.44) | KMOMCL1KDM4E | |
| SCHEMBL13118050 | 0.68 | AKR1C2 (0.41) | KDM4EKDM5AKDM5BAKR1C2AKR1C1 | |
| SCHEMBL13118020 | 0.67 | HSD17B1 (0.43) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426453-B2 | Treatment of a stomach or small intestine ulcer with 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid | ASTELLAS PHARMA INC. (JP) | 2013-04-23 | — | — | US | disclosed |
| US-8067446-B2 | Methods for treating an ulcer of the small intestine and stomach | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110281919-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| US-7820700-B2 | 2-phenylpyridine derivative | ASTELLAS PHARMA INC. (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20070275950-A1 | 2-Phenylpyridine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275950-A1 | 2-Phenylpyridine Derivative | NLRP3, XDH, UACA | KMO 620/4885MCL1 2860/4885KDM4E 739/4885 |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | KMO 1070/4885MCL1 4780/4885KDM4E 4662/4885 |
| US-20110281919-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | KMO 1070/4885MCL1 4780/4885KDM4E 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.